The Future of Metastatic and Unresectable Melanoma Treatment

Author(s):

The panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.

EP: 1.The Role of Biomarker Testing in the Management of Metastatic Melanoma

EP: 2.Best Practices for Biomarker Testing in Metastatic Melanoma

EP: 3.Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma

EP: 4.Treatment Options for Patients With Metastatic Melanoma With a BRAF Mutation

EP: 5.Factors Influencing Treatment Decision-Making In Patients With BRAF-Mutated Metastatic Melanoma

EP: 6.Frontline Treatment Options for Patients With BRAF-Mutated Metastatic Melanoma

EP: 7.Common Adverse Effects Seen With BRAF/MEK Inhibitor Therapy in Patients With BRAF-Mutated Metastatic Melanoma

EP: 8.Choosing Between Available Combination BRAF/MEK Inhibitor Options for Patients With BRAF-Mutated Metastatic Melanoma

EP: 9.Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial

EP: 10.Efficacy and Safety of Rechallenge With BRAF/MEK Inhibitors in Patients With BRAF-Mutated Metastatic Melanoma

EP: 11.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Asymptomatic Brain Metastases

EP: 12.Treatment Approaches For Patients With BRAF-Mutated Melanoma and Symptomatic Brain Metastases

EP: 13.Key Data on Combination Immunotherapies in BRAF-Mutated Melanoma with Brain Metastases

Now Viewing